-$0.56 Earnings Per Share Expected for EXACT Sciences Co. (NASDAQ:EXAS) This Quarter

Wall Street brokerages expect EXACT Sciences Co. (NASDAQ:EXAS) to post ($0.56) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for EXACT Sciences’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.52). EXACT Sciences posted earnings per share of ($0.30) in the same quarter last year, which would indicate a negative year-over-year growth rate of 86.7%. The company is scheduled to announce its next earnings results after the market closes on Tuesday, July 30th.

On average, analysts expect that EXACT Sciences will report full-year earnings of ($2.18) per share for the current financial year, with EPS estimates ranging from ($2.26) to ($2.06). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.38) to ($0.49). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover EXACT Sciences.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.01). EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The firm had revenue of $162.00 million during the quarter, compared to analysts’ expectations of $153.07 million. During the same period in the prior year, the company posted ($0.33) earnings per share. The company’s revenue for the quarter was up 79.4% on a year-over-year basis.

EXAS has been the topic of a number of recent analyst reports. Craig Hallum increased their price objective on shares of 1-800-Flowers.Com from $26.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Jefferies Financial Group increased their price objective on shares of EXACT Sciences from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Canaccord Genuity increased their price objective on shares of TELUS from C$51.00 to C$52.00 in a research report on Wednesday, May 1st. BTIG Research increased their price objective on shares of Apple to $234.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, BidaskClub raised shares of Misonix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 3rd. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. EXACT Sciences currently has a consensus rating of “Buy” and an average target price of $108.45.

Several institutional investors have recently modified their holdings of the company. IFM Investors Pty Ltd acquired a new position in shares of EXACT Sciences in the 2nd quarter valued at $961,000. Legacy Financial Strategies LLC acquired a new position in shares of EXACT Sciences in the 2nd quarter valued at $215,000. Nisa Investment Advisors LLC boosted its holdings in shares of EXACT Sciences by 779.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 27,250 shares of the medical research company’s stock valued at $3,217,000 after buying an additional 24,150 shares in the last quarter. Orgel Wealth Management LLC acquired a new position in shares of EXACT Sciences in the 2nd quarter valued at $224,000. Finally, Handelsbanken Fonder AB boosted its holdings in shares of EXACT Sciences by 18.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 190,000 shares of the medical research company’s stock valued at $22,428,000 after buying an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Shares of NASDAQ:EXAS traded down $1.24 during trading hours on Thursday, reaching $114.95. The stock had a trading volume of 921,298 shares, compared to its average volume of 1,713,290. EXACT Sciences has a 1 year low of $47.78 and a 1 year high of $121.98. The business’s 50 day moving average is $111.70. The company has a quick ratio of 8.13, a current ratio of 8.39 and a debt-to-equity ratio of 1.02. The stock has a market cap of $14.83 billion, a PE ratio of -84.52 and a beta of 1.65.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: How does the Beige Book influence monetary policy?

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.